Asthma is a complex respiratory disease that varies in severity and response to treatment.
Several asthma phenotypes with unique clinical and inflammatory characteristics have been …

Background With the introduction of different targeted therapies for type 2 (T2)-high asthma,
there is an urgent need for markers to guide the choice of treatment. T2-high asthma …

Although the complex disease of asthma has been defined as being heterogeneous, the
extent of its endophenotypes remains unclear. The pharmacological approach to initiating …

Asthma is a complex respiratory disorder characterized by marked heterogeneity in
individual patient disease triggers and response to therapy. Several asthma phenotypes …

Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging
as a unifying feature of both classically defined allergic diseases, such as asthma, and a …

Patients with severe asthma that remain uncontrolled incur significant medical burden and
healthcare costs. Severe asthma is a heterogeneous airway disorder with complex …

Objectives To review current thinking regarding the role of personalized phenotype-driven
as opposed to broad guideline-based therapies in asthma and to speculate on the relative …

The model of asthma as a single entity has now been replaced by a much more complex
biological network of distinct and interrelating inflammatory pathways. The term asthma is …

Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …

Monoclonal antibodies targeting IgE or the type-2 cytokines interleukin (IL)-4, IL-5 and IL-13
are proving highly effective in reducing exacerbations and symptoms in people with severe …